E3 Ligase Ligand-Linker Conjugate

E3 ligase ligand-linker conjugates combine a ligase ligand and a linker in one ready-to-couple PROTAC building block. Attaching such a conjugate to a target-protein ligand completes a proteolysis-targeting chimera (PROTAC) in a final coupling step. Many conjugates in this category carry a cereblon ligand derived from pomalidomide, lenalidomide or thalidomide, for example Pomalidomide-PEG4-C2-NH2 and Lenalidomide-C5-NH2. Others are built on von Hippel-Lindau (VHL) ligands, such as (S,R,S)-AHPC-C3-NH2 and VH032-thiol-C6-NH2. Terminal amines, acids and azides allow attachment by amide coupling or click chemistry.

5 Items

  • A 410099.1, amine-Boc hydrochloride
    Cat. No.
    A79950

    A 410099.1, amine-Boc hydrochloride

    A 410099.1, amine-Boc hydrochloride, serves as a functionalized inhibitor of apoptosis proteins (IAP) ligand. This compound is instrumental in the synthesis of PROTACs, particularly those targeting Bruton's tyrosine kinase (BTK), exemplified by PROTACs 4 and 5. It is a valuable tool for researchers exploring targeted protein degradation and its applications in therapeutic development.

    2 mg
    $30.00
    5 mg
    $80.00
    All 6 sizes
  • Thalidomide-O-C3-azide
    Cat. No.
    A80009

    Thalidomide-O-C3-azide

    Thalidomide-O-C3-azide is a modified form of the cereblon (CRBN) inhibitor, Thalidomide, featuring an azide group that enables efficient insertion into click chemistry reactions. This compound undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, making it a valuable tool for the synthesis of E3 ubiquitin ligase ligand-linker conjugates. Thalidomide-O-C3-azide is primarily utilized in the development of PROTACs, facilitating targeted protein degradation studies and advancing research in cellular signaling and therapeutic applications.

    10 mg
    $280.00
    25 mg
    $540.00
    All 2 sizes
  • Thalidomide-O-C5-azide
    Cat. No.
    A80107

    Thalidomide-O-C5-azide

    Thalidomide-O-C5-azide is a specialized E3 ubiquitin ligase ligand-linker conjugate, derived from the CRBN inhibitor Thalidomide. This compound features an azide group capable of participating in copper-catalyzed azide-alkyne cycloaddition reactions, making it suitable for use in the synthesis of PROTACs. Thalidomide-O-C5-azide facilitates targeted protein degradation, making it a valuable tool in chemical biology and therapeutic research applications.

    10 mg
    $280.00
    25 mg
    $540.00
    All 2 sizes
  • AhR Ligand-Linker Conjugates 1
    Cat. No.
    A80136

    AhR Ligand-Linker Conjugates 1

    Synonyms: E3 Ligase Ligand-Linker Conjugates 57

    AhR Ligand-Linker Conjugates 1 is designed as an E3 ubiquitin ligase ligand-linker conjugate that incorporates an IAP (inhibitor of apoptosis) ligand alongside a SNIPER (Specific and Pioneering IAP-medited Protein elimination) linker. This reagent enables the targeted degradation of specific proteins through the recruitment of E3 ligases. Its applications extend to drug discovery and the study of protein regulation through the ubiquitin-proteasome system, facilitating advancements in therapeutic strategies.

    Out of stock

    All 3 sizes
  • A 410099.1, amine-Boc
    Cat. No.
    A80236

    A 410099.1, amine-Boc

    A 410099.1, amine-Boc is a functionalized inhibitor of apoptosis protein (IAP) ligand that serves as a valuable building block for synthesizing proteolysis-targeting chimeras (PROTACs). This compound is particularly useful in the development of PROTACs that target Bruton's tyrosine kinase (BTK), showing promise for applications in cancer research and therapeutic development. Its ability to help modulate protein degradation makes it a potent tool in the exploration of novel treatment strategies.

    25 mg
    $1,275.00
    All 1 sizes

5 Items

Added to your cart

View Cart Checkout

    Loading...